Most of the evidence concerns the SF-36 and EQ-5D , and for these instruments there was evidence for known group validity .
Although the evidence base is limited in a number of important respects , including problems with the measures used to develop constructs in the validation studies , it is sufficient to raise doubts about the use of generic measures of health like the EQ-5D and SF-36 in patients with schizophrenia
OBJECTIVES Generic health status measures such as the short form health survey ( SF-36 ) and EuroQol-5D ( EQ-5D ) are increasingly being used to inform health policy .
They are cl aim ed to be applicable across disease areas and have started to be used within mental health research .
This review aims to assess the construct validity and responsiveness of four generic health status measures in schizophrenia , including the preference-based SF-6D and EQ-5D .
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
UNLABELLED Schizophrenia leads to impairments in mental , social , and physical functioning , which should be included in evaluations of treatment . OBJECTIVES This study was design ed to determine the reliability and validity of the Medical Outcomes Study Short Form Health Survey ( SF-36 ) for schizophrenic patients , to characterize perceived functioning and well being and to compare short-term change in SF-36 scores for patients treated with olanzapine or haloperidol .  RESEARCH DESIGN Data were obtained from a r and omized , double-blind trial comparing these agents for safety , efficacy , and cost effectiveness . A 6-week acute treatment portion preceded a 46-week " responder extension " phase . SUBJECTS A sub sample ( n = 1,155 ) completing a pre-treatment SF-36 provided data for this study . MEASURES Psychometric analyses were conducted , and perceived level of functioning was compared with that for the US adult population . Change from baseline to 6 weeks was examined by treatment group . RESULTS Clear evidence was obtained for the instrument 's reliability and validity for these patients . There were marked deficits in General health , Vitality , Mental health , Social functioning , and in Role limitations result ing from both physical and emotional problems . Olanzapine-treated patients improved in 5 of 8 domains to a significantly greater degree than did haloperidol patients . CONCLUSIONS The SF-36 can be a reliable and valid measure of perceived functioning and well being for schizophrenic patients . The perceptions of functioning can be valuable indices of disease burden and can help to demonstrate the effectiveness of newer antipsychotic medications such as olanzapine
Most of the evidence concerns the SF-36 and EQ-5D , and for these instruments there was evidence for known group validity .
Although the evidence base is limited in a number of important respects , including problems with the measures used to develop constructs in the validation studies , it is sufficient to raise doubts about the use of generic measures of health like the EQ-5D and SF-36 in patients with schizophrenia
OBJECTIVES Generic health status measures such as the short form health survey ( SF-36 ) and EuroQol-5D ( EQ-5D ) are increasingly being used to inform health policy .
They are cl aim ed to be applicable across disease areas and have started to be used within mental health research .
This review aims to assess the construct validity and responsiveness of four generic health status measures in schizophrenia , including the preference-based SF-6D and EQ-5D .